News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Data from the Phase III study showed that efgartigimod achieved the primary endpoint of total IgG reduction from the baseline on the 29th day of observation.
Shenandoah Biotechnology is a Warminster, Pennsylvania-based firm that manufactures recombinant proteins, including growth factors and cytokines.
Like Elizabeth Holmes, Ramesh Balwani faces multiple counts of fraud related to the business practices of Theranos.
Locus Biosciences’ CRISPR-Cas3-enhanced bacteriophage (crPhage™) product attacks harmful bacteria in the microbiome while sparing human cells.
In the age of COVID-19, moving to a remote workforce is a necessary but often challenging task. To help, we’ve compiled some tips that can help you while managing a remote workforce.
Aerium Therapeutics has officially launched following a successful Series A funding round led by seed investor Omega Funds.
Aligos Therapeutics, headquartered in South San Francisco, halted the development of ALG-020572, which was being developed in patients with chronic hepatitis B (CHB).
In the interim, Daniel Faga will take the helm as president and CEO after Hamza Suria let go of his executive functions.
Esai, Biogen, Diadem and ProMis all presented their findings on biomarker research at this year’s International Conference on Alzheimer’s and Parkinson’s Diseases.
Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.